A comparison of gestational days gained with oral terbutaline versus continuous subcutaneous terbutaline in women with twin gestations

被引：9

作者：

Lam F. ^{[1
]}

Bergauer N.K. ^{[2
]}

Coleman S.K. ^{[2
]}

Stanziano G.J. ^{[2
]}

Jacques D. ^{[2
]}

机构：

[1] California Pacific Medical Center, San Francisco, CA

[2] Matria Healthcarem Inc., Marietta, GA

来源：

Journal of Perinatology | 2000年 / 20卷 / 7期

关键词：

D O I：

10.1038/sj.jp.7200424

中图分类号：

学科分类号：

摘要：

OBJECTIVE: To compare gestational days gained with oral versus subcutaneous terbutaline for maintenance tocolysis. STUDY DESIGN: In retrospective fashion 386 women enrolled in an outpatient preterm labor identification program met the following criteria: twin gestation, development of threatened preterm labor resulting in treatment with oral terbutaline, and subsequent recurrence of threatened preterm labor resulting in treatment with continuous subcutaneous terbutaline. The primary outcome was gestational days gained with oral terbutaline versus gain with continuous subcutaneous terbutaline. RESULTS: There were significantly more days gained during subcutaneous treatment than during oral treatment (34.0±19.8 versus 19.3±15.3 days). Thirty-three percent of desired prolongation was achieved with oral terbutaline, whereas 79% of desired prolongation was achieved with subcutaneous terbutaline (p<0.001). Patients gained a mean of 53.4±21.4 days overall with outpatient tocolysis. The mean gestational age at delivery was 35.2±1.9 weeks. CONCLUSION: Continuous subcutaneous terbutaline was superior to oral terbutaline in prolonging gestation in women with twin gestations. © 2000 Nature America Inc.

引用

页码：408 / 413

页数：5

共 27 条

[1]

Ventura S.J., Martin J.A., Curtin S.C., Mathews T.J., Report of final natality statistics, 1996, Monthly Vital Statistics Report, 46, 11, (1998)

[2]

Goldenberg R.L., Iams J.D., Miodovnik M., Et al., NICHHDMFMUN. The preterm prediction study, risk factors in twin gestations, Am J Obstet Gynecol, 175, pp. 1047-1053, (1996)

[3]

Treatment of preterm labor with the beta-agonist ritodrine, N Engl J Med, 327, pp. 308-312, (1992)

[4]

Chau A.C., Gabert H.A., Miller J.M., A prospective comparison of terbutaline and magnesium for tocolysis, Obstet Gynecol, 80, pp. 847-851, (1992)

[5]

Rust O.A., Bofill J.A., Arriola R.M., Andrew M.E., Morrison J.C., The clinical efficacy of oral tocolytic therapy, Am J Obstet Gynecol, 175, pp. 838-842, (1996)

[6]

How H.Y., Hughes S.A., Vogel R.I., Gall S.A., Spinnato J.A., Oral terbutaline in the outpatient management of preterm labor, Am J Obstet Gynecol, 173, pp. 1518-1522, (1995)

[7]

Macones G.A., Berlin M., Berlin J.A., Efficacy of oral beta-agonist maintenance therapy in preterm labor: A meta-analysis, Obstet Gynecol, 85, pp. 313-317, (1995)

[8]

Lewis R., Mercer B.M., Salama M., Walsh M.A., Sibai B.M., Oral terbutaline after parenteral tocolysis: A randomized, double-blind, placebo-controlled trial, Am J Obstet Gynecol, 175, pp. 834-837, (1996)

[9]

Copper R.L., Goldenberg R.L., Creasy R.K., Et al., A multicenter study of preterm birth weight and gestational age-specific neonatal mortality, Am J Obstet Gynecol, 168, pp. 78-84, (1993)

[10]

McCormick M.C., The contribution of low birth weight to infant mortality and childhood morbidity, N Engl J Med, 312, pp. 82-90, (1985)

← 1 2 3 →